



Low Pre-Adolescent Vaccine Rates: Best Practices for Promoting Vaccines

Provider Action Requested: Increase the number of members receiving all recommended pre-adolescent vaccines including HPV.

Immunizations for Adolescents (IMA-2) rates of preteens receiving all meningococcal, Tdap, and HPV vaccines are lower than for any single vaccine given to preteens. BCBSTX goals for 2021 are to increase the rate of preteens (ages 9 through 12) receiving all three recommended vaccines in order to prevent infections, illness, and cancers.

Best practices and tools for completing immunizations for pre-adolescents:

- Make strong recommendations – vaccines prevent illness, infections, and cancers
- Bundle vaccines
- Remind members that vaccines are due
- Use [ImmTrac](#) to record complete vaccine history and identify members needing outreach
 - [DSHS ImmTrac User Training](#)
 - [CDCP Videos for Providers and Parents](#)
- [5 Ways to Boost Your HPV Vaccination Rates. CDCP. \(2020, June 29\)](#)
- [Toolkit for Pediatricians](#) - HPV Champion toolkit from the American Academy of Pediatrics
- [Merck webinar on vaccine confidence and addressing family concerns](#)

BCBSTX Reference Guides:

- [Child and Adolescent Tip Sheet](#)
- [HEDIS Billing Guide](#)
- [Using BCBSTX Indices for Performance](#)

Highlighted below: 2019 rates for Combination 2 (all 3 recommended vaccines) are low.

Line of Business	Description	Completion
CHIP, STAR, and STAR Kids	Combination 1 ((Meningococcal, Tdap)	66.47%
	Combination 2 (Meningococcal, Tdap, HPV)	26.85%
	HPV	29.84%
	Meningococcal conjugate	69.28%
	Tdap	69.58%
CHIP	Combination 1 ((Meningococcal, Tdap)	73.81%
	Combination 2 (Meningococcal, Tdap, HPV)	32.74%
	HPV	34.52%
	Meningococcal conjugate	76.79%
	Tdap	77.38%



BlueCross BlueShield of Texas

STAR	Combination 1 ((Meningococcal, Tdap)	69.98%
	Combination 2 (Meningococcal, Tdap, HPV)	28.80%
	HPV	31.89%
	Meningococcal conjugate	72.89%
	Tdap	71.95%
STAR Kids	Combination 1 ((Meningococcal, Tdap)	55.93%
	Combination 2 (Meningococcal, Tdap, HPV)	20.34%
	HPV	23.52%
	Meningococcal conjugate	58.47%
	Tdap	61.44%

The above material is for informational purposes only and is not a substitute for the independent medical judgment of a physician or other health care provider. Physicians and other health care providers are encouraged to use their own medical judgment based upon all available information and the condition of the patient in determining the appropriate course of treatment. The fact that a service or treatment is described in this material is not a guarantee that the service or treatment is a covered benefit and members should refer to their certificate of coverage for more details, including benefits, limitations and exclusions. Regardless of benefits, the final decision about any service or treatment is between the member and their health care provider.

[By clicking this link](#), you will go to a new website/app ("site"). This new site may be offered by a vendor or an independent third party. The site may also contain non-Medicare related information. In addition, some sites may require you to agree to their terms of use and privacy policy.

Blue Cross and Blue Shield of Texas, a Division of Health Care Service Corporation, a Mutual Legal Reserve Company, an Independent Licensee of the Blue Cross and Blue Shield Association